摘要
目的探讨核苷类药物在乙型肝炎后肝硬化治疗中的临床疗效。方法抽取88例乙型肝炎后肝硬化患者并随机分组,甲组(n=44)应用恩替卡韦,乙组(n=44)应用阿德福韦酯,就2组患者用药12个月后乙肝表面抗原(HBe Ag)转阴率和乙肝病毒(HBV DNA)含量进行统计学分析。结果甲组HBe Ag转阴率是36.36%,平均HBV DNA含量是(3.18±0.99)log拷贝/ml;乙组HBe Ag转阴率是15.91%,平均HBV DNA含量是(4.01±1.22)log拷贝/ml;上述指标的组间对比均差异有统计学意义(P<0.05,P<0.01)。结论核苷类药物在乙型肝炎后肝硬化治疗中的临床疗效确切,可将恩替卡韦作为首选治疗药品。
Objective To investigate the clinical efficacy of nucleoside analogues in the treatment of hepatitis B cirrhosis. Methods A total of 88 cases of patients with liver cirrhosis after hepatitis B and randomly divided into group A（n=44） with entecavir, group B（n=44） application of adefovir, hepatitis B surface antigen（HBe Ag） seroconversion rate and hepatitis B virus（HBV DNA） content were statistically analyzed in 2 groups of patients after 12 months. Results The negative rate of HBe Ag was 36.36%, the average HBV DNA content was（3.18±0.99） log copy/ml; The negative rate of HBe Ag in group B was 15.91%, and the mean HBV and DNA content was（4.01±1.22） log copy/ml; There were statistically significant differences between the two groups（P〈0.05, P〈0.01）. Conclusion Nucleoside analogues has good clinical efficacy in the treatment of hepatitis B cirrhosis, and entecavir is the first choice for the treatment.
出处
《中国继续医学教育》
2017年第18期158-159,共2页
China Continuing Medical Education
